Stock Price
277.00
Daily Change
-1.32 -0.47%
Monthly
0.72%
Yearly
25.61%
Q4 Forecast
261.27

EPS Reference Time Actual Consensus Previous
2026-10-27 FY2026Q3 AM 3.24 3.00
2026-07-28 FY2026Q2 AM 3.15 3.04 2.81
2026-05-05 FY2026Q1 AM 2.90 2.82 2.70
2026-02-05 FY2025Q4 AM 3.42 3.4 3.12
2025-10-28 FY2025Q3 AM 3.00 2.98 2.84



Peers Price Chg Day Year Date
Celltrion 194,400.00 100.00 0.05% 12.43% Oct/23
Cspc Pharmaceutical 8.35 -0.01 -0.12% 5.83% Oct/23
Sino Biopharmaceutical 5.00 0.02 0.40% -28.16% Oct/23
Zhangzhou Pientzehuang Pharmaceutical 123.15 1.64 1.35% -31.86% Oct/23
Kangmei Pharma 1.27 0.02 1.60% -37.75% Oct/23
Agilent 170.93 -2.96 -1.70% 15.47% Oct/23
Accenture 245.81 -13.23 -5.11% -0.87% Oct/23
Elevance Health 442.94 -2.34 -0.53% 29.38% Oct/23
Bruker 57.05 -0.26 -0.45% 43.67% Oct/23
Cardinal Health 252.81 -2.83 -1.11% 56.16% Oct/23

Indexes Price Day Year Date
US Index 500 7652 -11.07 -0.14% 12.67% Oct/23

IQVIA Holdings Inc traded at $277.00 this Friday October 23rd, decreasing $1.32 or 0.47 percent since the previous trading session. Looking back, over the last four weeks, IQVIA Holdings lost 0.72 percent. Over the last 12 months, its price rose by 25.61 percent. Looking ahead, we forecast IQVIA Holdings Inc to be priced at 261.27 by the end of this quarter and at 245.08 in one year, according to Trading Economics global macro models projections and analysts expectations.

IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.